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Background: Some natural substances may affect the expression of
microRNAs (miRNAs) in humans. However, it is unclear whether
this effect can be induced by the ingestion of whole foods con-
taining these natural substances.
Objective: We investigated whether ingestion of the whole food
FFC® Pairogen affects the expression of miRNAs in humans.
Design: This was a pilot study and part of a randomized controlled
trial. Four subjects ingested the test material daily for 8 weeks
(three times 180 ml bottles a day, morning, noon and evening; a
total of 540 ml per day). The study did not include control subjects.
Results: Several miRNAs showed differential expression. The
expression of two miRNAs, hsa-let-7c and hsa-miR-92a-2-5p,
changed in three of the four subjects, who had lower concentra-
tion of serum total antioxidant status. The expression of hsa-let-7c
increased and that of hsa-miR-92a-2-5p decreased.
Conclusions: The expression of hsa-let-7c and hsa-miR-92a-2-5p has
been linkedwith lungcancermanifestation.The increasedexpressionof
hsa-let-7c and the decreased expression of hsa-miR-92a-2-5p suggest
possibleoncogenesuppressive functionsof thesemiRNAs.The ingestion
of FFC® Pairogen may have a positive effect on cancer prevention.
© 2015 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).fax: þ81 3 3818 0617.
i).
r Ltdonbehalfof EuropeanSociety forClinicalNutrition andMetabolism. This is
//creativecommons.org/licenses/by/4.0/).
T. Hiroe et al. / Clinical Nutrition Experimental 2 (2015) 1e821. IntroductionTo achieve a long life, people are increasingly being encouraged to lead active and healthy life-
styles. Many health and nutritional supplements have been marketed with phrases such as 'enhancing
your immune system' and contain antioxidant components including resveratrol, polyphenols, lyco-
pene and vitamins A, B9, D, and E. For most people, it would be impossible to take all of these separate
health supplements. Therefore, whole foods or beverages with the potential for immune system
enhancement would be a more convenient choice. In this context, cancer prevention is the most
common concern because the mortality rate from cancer in people over 60 years old dramatically
increases with age [1]. Food is vital for human health and can reduce the risks of various illnesses.
These functions of food have been evaluated by analysis of various biomarkers, through hemanalysis,
urinalysis and physical examination. In recent years, attempts have been made to evaluate human
health status and/or contraction of diseases in terms of microRNAs (miRNAs), which are small, non-
coding, single-stranded RNAs that negatively regulate gene expression either by translational inhi-
bition or exonucleolytic mRNA decay. Experiments using rats and mice and in vitro studies have
demonstrated that the modulation of miRNAs by dietary and pharmacological agents can induce cell
growth, cell cycle regulation and mutation, as well as inhibit stress responses, angiogenesis, cell
proliferation and inﬂammation [2].
MicroRNAs are classiﬁed into various families or clusters and speciﬁc physiological features of
some have been investigated. For example, let-7c family miRNAs act as tumor suppressor genes by
targeting cell cycle related genes and inhibiting cell division and the progression of lung cancer
[3,4]. The miRNA17-92 cluster is oncogenic [4], its over-expression contributes to the manifestation
of lung cancer [5], it is involved with mastocarcinoma through the down-regulation of estrogen
receptors [6] and it is up-regulated in patients with ovarian epithelial carcinoma [7]. Furthermore,
Dhar et al. reported in their in vitro study that resveratrol, a component of various berries and red
wine, up-regulated tumor suppressor PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) in prostate cancer cells [8], indicating that miRNA expression related to tumorigenesis
or tumor suppression can be changed by food ingestion. However, most studies that have discussed
the relationship between miRNAs and food ingestion investigated a single nutrition element such
as a vitamin, polyphenol or isoﬂavone [9]. Furthermore, very few miRNA studies using whole foods
or beverages have been performed, despite evaluation of nutrition through ingestion of a whole
food or beverage being more realistic of human diet. In addition, most studies discussing the
relationship between food ingestion and miRNAs have focused on effects on cell lines [10] and very
few have discussed effects on the human body. Therefore, these relationships require evaluation
in vivo.
In our previous study, we found that the beverage FFC® Pairogen Special Three had potential as an
immune activator and, therefore, could have a great inﬂuence on human health and disease prevention
[11]. Now we used FFC® Pairogen that has similar ingredients to FFC® Pairogen Special Three (Table 1).Table 1
Test material ingredients (in 180 ml).
Material name FFC® Pairogen
Form Liquid
Ingredients Glucose-fructose syrup, rice vinegar, honey, apple vinegar, Japanese
persimmon vinegar, Japanese apricot vinegar, apple juice, substances
extracted from Japanese apricot, galactooligosaccharide. citric acid. Vitamin C,
malic acid, stevia, ﬂavors, Vitamin B2, Vitamin B6
Nutrition facts Protein 0 mg
Lipid 0 mg
Carbohydrate 9200 mg
Sodium 59.5 mg
Energy 37 kcal
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expression of miRNAs that have possible anti-oxidation effects. In this report, we discuss whether the
effect of a food or beverage on human physiology can be evaluated by the expression of various
miRNAs.2. Subjects and methods
2.1. Study design
This study was designed as a case study as part of a randomized controlled trial using FFC® Pairogen
provided by the Akatsuka Corporation (Table 1). This study was registered in the Japanese University
Hospital Medical Information Network as UMIN000012608.2.2. Participants
The four subjects were 50.3 ± 2.6 years old selected from among those enrolled in our previous
antioxidant study (Hiroe et al. unpublished) that adhered to the following protocol.
A total of 30 healthy volunteers between 40 and 60 years old were recruited to undergo a
screening test held at the Seishin-kai Medical Association Inc., Takara Medical Clinic. Participants
included in the trial were individuals who felt fatigued daily. People were excluded for the following
reasons: previous history of cardiac arrest or cardiac infarction; presence of arterial ﬁbrillation,
cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes,
dyslipidemia, hypertension, and other chronic conditions; use of medications, including Chinese
medicines and dietary supplements; an allergy to medicines and foods related to the test materials
of the trial; pregnancy, lactation, or desire to become pregnant during the test period; being enrolled
in another clinical study; and judgment by the trial physician to be unsuitable for this trial. Twenty-
two female participants were selected based on the concentration of serum total antioxidant status
(STAS) in the screening test. No men had passed the screening test. In fact, only 2 had been eligible
for the trial, so they were not included because of the possibility of biased results compared to the
22 women.
In this present study, blood samples in 4 participants were collected for microarray analysis while
those in other 18 participants were not collected (Fig. 1). The sample size was determined as much as
the budget of this trial limited. Four subjects were included from FFC® Pairogen group of 11 subjects at
ﬁrst allocation for our previous study (unpublished), and had relatively lower STAS in the group
(Fig. 1).
This trial was conducted from 20 May 2013 to 23 October 2013. All the participants gave written
informed consent before participating in the screening test. This trial was conducted according to the
Declaration of Helsinki and approved by the ethics committee of the Seishin-kai Takara Medical Clinic
before start of the trial.2.3. Study products
The participants consumed 1 pack of FFC® Pairogen 3 times daily. Each pack of FFC® Pairogen
contained 180 ml of the product; therefore, daily consumption was 540 ml of FFC® Pairogen. The FFC®
Pairogen used in this trial was the product of the Akatsuka Co., Ltd., with which the ﬁrst and second
authors are afﬁliated. The participants were not restricted to take any waters or drinks other than their
trial beverages, except for dietary supplements.2.4. RNA extraction and miRNA expression proﬁling
We measured the expression of miRNAs. RNA was extracted from the blood serum using 3D-Gene
RNA extraction reagent from liquid sample (Toray, Kamakura, Japan) according to the manufacturer's
Fig. 1. Subject ﬂowchart. Four participants who showed low STAS score had FFC® Pairogen in the intake period for that evaluate
miRNA expressions were investigated.
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Kamakura, Japan). Labeled RNAs were hybridized onto 3D-Gene Human miRNA Oligo chips (Toray,
Kamakura, Japan). The annotation and oligonucleotide sequences of the probes were conformed to the
miRBase miRNA data base (http://microrna.sanger.ac.uk/sequences/). After stringent washes, ﬂuores-
cent signals were scanned with the 3D-Gene Scanner (Toray Industries) and analyzed using 3D-Gene
Extraction software (Toray Industries).
The raw data of each spot was normalized by substitution with a mean intensity of the background
signal determined by all blank spots' signal intensities of 95% conﬁdence intervals. Measurements of
spots with the signal intensities greater than 2 standard deviations (SD) of the background signal
intensity were considered to be valid. A relative expression level of a given miRNA was calculated by
comparing the signal intensities of the valid spots throughout the microarray experiments. The
Normalized data were globally normalized per array, such that the median of the signal intensity was
adjusted to 25.
ThemiRNAs inwhich abundance had changed in the same direction in three out of the four subjects
were selected. A miRNA was deﬁned as ‘up-regulated’ when its abundance was more than twice that
before intake, andwhen the abundancewas less than half that before intake, themiRNAwas deﬁned as
‘down-regulated’. We then deﬁned the physiological signiﬁcance of each miRNA that had clear
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and then the name of the gene in which the miRNA gene was located.3. Results
The expression levels of miRNAs for all four subjects are shown in Fig. 2. The increased and
decreased expression of miRNAs between Exam 1 (before FFC® Pairogen ingestion) and Exam 2 (after
ingestion) are illustrated for each subject in Fig. 3. Among the 362 miRNAs detected, eleven showed
signiﬁcant log2 fold-changes after ingestion, and were chosen for further analysis. Table 2 shows the
levels of miRNA expression after FFC® Pairogen ingestion. Although none of the miRNAs showed
augmentation of expression in all four subjects, the expression of hsa-let-7c and hsa-miR-4755-3p was
increased in three of the four subjects while the expression of hsa-miR-1238-3p and hsa-miR-6717-5p
was decreased in all four subjects. The expression of seven miRNAsdhsa-miR-671-5p, hsa-miR-92a-2-
5p, hsa-miR-1238-3p, hsa-miR-3131, hsa-miR-4298, hsa-miR-642a-3p and hsa-miR-652-5pdwas
decreased in three of the four subjects.Fig. 2. Log2 fold-change in the expression of the 362 microRNAs analyzed pre- and post-test in all subjects. Green and red indicate
enhancement and suppression of expression compared with that at week-0, respectively.
Fig. 3. Comparison of expression for all miRNAs between Exam 1 and Exam 2 for each subject. The horizontal axis shows miRNA
expression on Exam 1 and the vertical axis shows expression on Exam 2. The red line indicates the value in Exam 1 was equal to that
in Exam 2. If a point is under the red line, the miRNAwas induced on Exam 2. Otherwise, the miRNAwas suppressed on Exam 2. The
two blue lines show double or halved expression levels.
Table 2
Results of miRXA examination.
miRNA Increase rate of regulation after ingesting for all subjects Annotation GenBank code
subj. 6405 subj. 6406 subj. 6414 subj. 6415 Mean
Increased in all subjects
None e e e e e N/A N/A
Increased in three subjects
hsa-let-7c 0.92 5.44 3.16 2.95 3.12 Yesa MI0000064
hsa-miR-4755-3p 1.43 2.39 2.50 4.02 2.59 N/A MIMAT0019896
Decreased in all subjects
None e e e e e N/A N/A
Decreased in three subjects
hsa-miR-67l-5p 0.35 0.33 0.50 0.15 0.33 N/A MIMAT0003880
hsa-miR-92a-2-5p 0.44 0.34 0.90 0.35 0.51 Yesa MIMAT0004508
hsa-miR-1238-3p 0.41 0.45 0.73 0.33 0.4S N/A MIMAT0005593
hsa-miR-3131 0.51 0.24 0.47 0.40 0.41 N/A MI0014151
hsa-miR-4298 1.09 0.35 0.42 0.39 0.56 N/A MI0015830
hsa-miR-642a-3p 0.49 0.23 0.51 0.17 0.35 N/A MIMAT0020924
hsa-miR-652-5p 0.50 0.40 0.49 0.43 0.46 N/A MIMAT0022709
a Community annotation (Ref. [13]).
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The results of this study suggest that after the intake of FFC® Pairogen for 8 weeks, some miRNA
expressions changed, especially hsa-let-7c and hsa-miR-92a-2-5p.
hsa-let-7c targets cell cycle related genes, inhibits cell division [3,12], suppresses the manifestation
of lung cancer [3] and functions as a tumor suppressor gene [4]. In contrast, the miR-17-92 cluster and
hsa-miR-92-q-2-5p act as oncogenes when over-expressed [4], contribute to the manifestation of lung
cancer through over-expression [5], are involved with the manifestation of mastocarcinoma through
the down-regulation of estrogen receptors [6] and show increased expression in patients with ovarian
epithelial carcinoma [7].
The concurrent over-expression of hsa-let-7c and under-expression of hsa-miR-92-a-2-5p,
could be considered preventative for cancer [3,7] and, therefore, could serve as disease preventive
genes.
The daily intake of FFC® Pairogen may affect the systematic regulation of miRNAs correlated with
diseases and carcinomata. In addition, intake of another whole food could affect the expression of
miRNAs.
These results suggest that effects of whole foods ingested by humans could be evaluated through
analysis of miRNAs. However, the small sample of only four participants and the lack of control subjects
are limitations of this trial. And participants ingested FFC® Pairogen also with regular meals at each day
so that the miRNA expression changes did not directly determine by the ingestion. Moreover, this
preliminary study did not include any control groups thereby further studies could resolve this
problems including the number of subjects.
In conclusion, the functional effect of a whole food ingested by humans can be evaluated by the
comprehensive analysis of miRNAs.Conﬂict of interest
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